M&A / Deals Cardio biotech Kardigan binds off $400M upsized IPO BioSpaceAnalysts are cautiously optimistic about an IPO rebound for biopharma.CardiovascularRead full story pharminent June 18, 2026 (Last updated: June 19, 2026) BioSpace Analysts are cautiously optimistic about an IPO rebound for biopharma. Cardiovascular Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: GSK claims FDA okay for first oral carbapenem antibioticNext: Heart drug biotech Kardigan raises $400m in upscaled IPO Related Stories M&A / Deals Biogen to acquire RayThera for up to $1bn pharminent June 19, 2026 M&A / Deals Heart drug biotech Kardigan raises $400m in upscaled IPO pharminent June 18, 2026 M&A / Deals LG AI Research and D&D Pharmatech sign agreement for oral peptide drugs pharminent June 18, 2026
